JPH0136444B2 - - Google Patents
Info
- Publication number
- JPH0136444B2 JPH0136444B2 JP56067071A JP6707181A JPH0136444B2 JP H0136444 B2 JPH0136444 B2 JP H0136444B2 JP 56067071 A JP56067071 A JP 56067071A JP 6707181 A JP6707181 A JP 6707181A JP H0136444 B2 JPH0136444 B2 JP H0136444B2
- Authority
- JP
- Japan
- Prior art keywords
- theophylline
- tablets
- tablet
- pharmaceutical tablet
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 163
- 229960000278 theophylline Drugs 0.000 claims description 81
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 40
- 235000019359 magnesium stearate Nutrition 0.000 claims description 20
- 210000002966 serum Anatomy 0.000 claims description 12
- 230000037406 food intake Effects 0.000 claims description 6
- 238000011287 therapeutic dose Methods 0.000 claims description 3
- 230000002459 sustained effect Effects 0.000 claims description 2
- 239000003826 tablet Substances 0.000 description 135
- 238000004090 dissolution Methods 0.000 description 27
- 229940079593 drug Drugs 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- 238000012360 testing method Methods 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 9
- 238000010828 elution Methods 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- 229940124630 bronchodilator Drugs 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 241001122767 Theaceae Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000013265 extended release Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000011436 cob Substances 0.000 description 1
- 235000021443 coca cola Nutrition 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000011418 maintenance treatment Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 229940101521 theophylline 300 mg Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000005353 urine analysis Methods 0.000 description 1
- -1 urine analysis Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14742980A | 1980-05-06 | 1980-05-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS57112322A JPS57112322A (en) | 1982-07-13 |
JPH0136444B2 true JPH0136444B2 (de) | 1989-07-31 |
Family
ID=22521536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP56067071A Granted JPS57112322A (en) | 1980-05-06 | 1981-05-06 | Low volume slow release theophylline tablet |
Country Status (4)
Country | Link |
---|---|
JP (1) | JPS57112322A (de) |
BE (1) | BE888697A (de) |
GR (1) | GR75250B (de) |
ZA (1) | ZA812861B (de) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3307382C2 (de) * | 1983-03-02 | 1990-01-25 | Hans-Peter 8022 Grünwald Walter | Arzneimittel, geeignet zur Behandlung von entzündlichen Veränderungen der Bronchialschleimhaut |
JPH04130607U (ja) * | 1991-05-22 | 1992-11-30 | ダイワラクダ工業株式会社 | 壁パネル用目地具 |
-
1981
- 1981-04-30 ZA ZA00812861A patent/ZA812861B/xx unknown
- 1981-05-06 JP JP56067071A patent/JPS57112322A/ja active Granted
- 1981-05-06 GR GR64861A patent/GR75250B/el unknown
- 1981-05-06 BE BE0/204704A patent/BE888697A/fr not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ZA812861B (en) | 1982-05-26 |
JPS57112322A (en) | 1982-07-13 |
GR75250B (de) | 1984-07-13 |
BE888697A (fr) | 1981-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4465660A (en) | Sustained release tablet containing at least 95 percent theophylline | |
US4837032A (en) | Theophylline sustained release tablet | |
KR20110133602A (ko) | 옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물 | |
JP5921513B2 (ja) | ナルトレキソンの徐放型配合物 | |
HUE030609T2 (en) | New pharmaceutical compositions for the treatment of insomnia | |
US4547358A (en) | Sustained release tablet containing at least 95 percent theophylline | |
PT85128B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo, como ingrediente activo, 4-(1-metil-4-piperidilideno)-4h-benzo-{4,5}ciclohepta{1,2-b}tiofeno--10(9h)-ona | |
Singh et al. | An overview on fast disintegrating sublingual tablets | |
RU2563190C2 (ru) | Лекарственное средство на основе сухих экстрактов лекарственных растений и способ его получения (варианты) | |
Sahoo et al. | Designing of orodispersible tablet of diethyl carbamazine citrate for the treatment of filariasis | |
JPH0136444B2 (de) | ||
IE51157B1 (en) | Sustained release theophylline tablet having reduced bulk | |
Chauhan et al. | Formulation and evaluation of fast dissolving tablets of telmisartan | |
KR100697093B1 (ko) | 비타민 c 및 감기 치료제를 함유하는 이중정 제형 및 그의제조방법 | |
Pedersen et al. | Absorption characteristics of once-a-day slow-release theophylline preparation in children with asthma | |
Tambe | Formulation and Evaluation of Paracetamol Effervescent Tablet | |
Desu | Formulation and evaluation of nateglinide dispersible tablet by direct compression method | |
US10849856B2 (en) | Melatonin mini-tablets and method of manufacturing the same | |
Hadi et al. | Formulation and Evaluation of Once Daily Sustained Release Matrix Tablets of Terbutaline Sulphate for the Treatment of Nocturnal Asthma | |
Alburyhi et al. | FORMULATION AND EVALUATION OF BISOPROLOL FAST DISSOLVING TABLETS | |
Bhowmik et al. | Formulation and Evaluation of Telmisartan Fast Dissolving Tablets by Direct Compression Method | |
Tizkam et al. | Preparation of a new dosage form of metoclopramide hydrochloride as orodispersible tablet | |
Nikita et al. | Formulation and evaluation of mouth dissolving tablets of Telmisartan | |
Hemalatha et al. | ORODISPERSIBLE TABLET BASED TECHNOLOGY FOR THE TREATMENT OF SCHIZOPHRENIA | |
Reza et al. | Formulation development of taste masked aceclofenac orodispersible tablets |